Anti-Diabetes Flashcards
Insulin of choice in emergent sitautions
IV regular insulin
Low risk of hypoglycemia insulins VRS High risk of hypoglycemia insulins. Name please
rapid acting (lispro, aspart, glulisine) and long acting (glargine, detremir) = low risk VRS higher risk: short acting (regular insulin) and intermediate (NPH)
drugs that can interefere with diabetic meds and make them more prone to hyPOglycemia
beta blockers - stop effects of catecholamines
EtOH - prevents gluconeogenesis
Salicylates - increases insulin secretion and acts a wee bit like insulin @ periphery
drugs that can interfere wtih diabetic meds and make pts more prone to hyPERglycemia
epinephrine, corticosteroids, atypical antipsychotics, HIV protease inhibitors = make tissue less responsive
phenyoin, clonidine, calcium channel blockers = decreased insulin secretion
diuretics = deplete K (alters ability of K to play roel in exocytosis of insulin in response to sugra SUR/KIR channel)
first gen sulfonylureas please
tobutamide - short duration of action
chlorporpamide - longer duration of action
a/se of chlorporpamide
hyperglycemia @ elderly = dont give
hyperemic flush @ OH = dont drink
SIADH = dont pee
DONT GIVE OLD, DONT DRINK LOTS, DONT PEE MUCH
second gen sulfonylureas, now preferred bc better a/se profile = ?
glyburide - hyperglycemia @ 20-30%
glupizine - hyperglycemia @ least DOC***
glimepride - hyperglycemia @ 3-4%
anti-diabetic drugs that cause WEIGHT GAIN
1) sulfonlyureas - tolbutamide, chlorpropamide, glyburide, glipizine, glimepride
2) meglinitides - repaglinide, nateglinide
Please name the Meglitinides
Repaglinide
Nateglinide
Describe kinetics and use of the meglitinides
shorter duration of action and more rapid onset than sulfonylureas –> thefeore used for post pradial (omit if you skip a meal)
A/se of meglitinides
repaglinide and natiglinide: hypoglycemia and weight gain
MOA of meglitinides and sulfonylureas
bind to SUR of ATP-K sensitive –> causes less K+ out of cell –> depolarizes –> opens vg Ca++ channels –> depolarizes –> exocytosis of insulin and increased transcription of insulin –> hurrah
MOA of metformin key words please
no insulin increase (decreases insulin levels due to improved glycemic control)
stops gluconeogen @ liver
increases insulin effects @ muscle and liver
Effects unique to metformin *small group too , high yeild probly
decreases TAG
does not cause weight gain
First line for DMii
metformin (because doesnt cause weight gain and decreases TAG)
When I say metformin, you think of this intracellular protein causeing all its effects
AMPK
A/se of metformin
a) gi messy time
b) B12 deficeincy - bc of gi messy time
c) lactic acidosis - bc liver cant use lactic acid for gluconeogenesis since metformin blocks it via AMPK
Dont use metformin for these 4 types of patients
liver dz
renal dz
OH-ics
hypoxic patients - resp dz
TZDs name them please
pioglitazide
rosiglitazone
MOA TZDs please
pioglitazide, rosiglitazone
a) decrease insulin resistance
b) agonists of PPARgamaa = alter gene expression and therefore take weeks to months to take effect